Adding Vancomycin to the Antimicrobial Prophylaxis Regimen of Cefazolin for patients undergone Arthroplasty
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 8th, 2023
|
Arthroplasty surgeries to replace or modify knee and hip joints are increasingly common as the population ages. During arthroplasty, first and second cephalosporins, such as cefazolin, are often used to prevent infections. However, with the rise of nosocomial infections caused by methicillin-resistant Staphylococcus aureus (MRSA), there is a need for more effective prophylaxis. To address this concern, the Australian National Health and Medical Research Council sponsored a study to assess the effectiveness of adding vancomycin to the prophylaxis regimen for patients undergoing arthroplasty surgery.
The phase 4 clinical trial involved 4113 participants, with an average age of 66 years. Half of the participants underwent knee joint arthroplasty, while the other half had hip joint arthroplasty. The participants had an average body mass index of approximately 30.7, with about 12% affected by diabetes and around 6% considered immunosuppressed. The participants were randomly assigned to receive either vancomycin or a saline placebo in addition to the standard cefazolin prophylaxis. Both antibiotics were administered intravenously, with cefazolin given at a dose of 2 grams and vancomycin at 1.5 grams. For patients weighing below 50 kilograms, the vancomycin dosage was reduced to 1.0 gram. The researchers observed that the rate of surgical site infection was 4.5% in the patients treated with vancomycin and cefazolin, while it was 3.5% in those who received the placebo and cefazolin. Consequently, the study concluded that the use of vancomycin does not significantly reduce the risk of surgical-site infection. Due to its lack of superiority, vancomycin should not be routinely used as prophylaxis but rather reserved as a last-resort antimicrobial agent to prevent the development of resistance.
The phase 4 clinical trial involved 4113 participants, with an average age of 66 years. Half of the participants underwent knee joint arthroplasty, while the other half had hip joint arthroplasty. The participants had an average body mass index of approximately 30.7, with about 12% affected by diabetes and around 6% considered immunosuppressed. The participants were randomly assigned to receive either vancomycin or a saline placebo in addition to the standard cefazolin prophylaxis. Both antibiotics were administered intravenously, with cefazolin given at a dose of 2 grams and vancomycin at 1.5 grams. For patients weighing below 50 kilograms, the vancomycin dosage was reduced to 1.0 gram. The researchers observed that the rate of surgical site infection was 4.5% in the patients treated with vancomycin and cefazolin, while it was 3.5% in those who received the placebo and cefazolin. Consequently, the study concluded that the use of vancomycin does not significantly reduce the risk of surgical-site infection. Due to its lack of superiority, vancomycin should not be routinely used as prophylaxis but rather reserved as a last-resort antimicrobial agent to prevent the development of resistance.